Patent Issued for Recombinant Nucleotide Sequence, Cell Or Vector Containing the Same and Method for Using Cell Containing the Same to Encode Anti-Polyethylene Glycol Monoclonal Antibodies
The patent's assignee for patent number 8507207 is
News editors obtained the following quote from the background information supplied by the inventors: "The present invention relates to a novel reporter gene system, and in particular relates to a method for using a recombinant nucleotide sequence encoding an anti-polyethylene glycol recombinant single chain membrane antibody as a reporter gene to monitor presence and distribution of a gene and a cell.
"Developing non-immunogic and specific reporter genes to monitor expressions and distributions of genes and cells in vivo is very important for the optimization of gene or cell therapy.
"Presently, there are two types of reporter genes for non-invasive imaging: (1) exogenous reporter genes: mainly from bacterium or virus of non-mammal systems, such as the gene of the herpesvirus thymidine kinase, the gene of the bacterial cytosine deaminase and the gene of the green fluorescent protein. Although exogenous reporter genes have specificities, the products thereof usually induce immune responses that result in tissue injury. Thus, exogenous reporter genes limit the continuous expression (long term) and orientation imaging of reporter genes, limiting clinical application; and (2) endogenous reporter genes: from such as human dopamine D2 and transferrin. Although endogenous reporter genes do not easily induce immune responses, dopamine D2 and transferrin are widely expressed in normal human body systems. Thus, endogenous reporter genes lack specificity and application thereof is limited. Therefore, developing low immunogic and highly specific reporter genes is desired. As such, a gene of an anti-polyethylene glycol membrane antibody which belongs to the exogenous reporter genes and meets the low immunogenicity and high specificity features and requirements of reporter genes is disclosed herein."
As a supplement to the background information on this patent, NewsRx correspondents also obtained the inventors' summary information for this patent: "The invention provides a recombinant nucleotide sequence, comprising the sequence of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 or SEQ ID No. 4, wherein the recombinant nucleotide sequence encodes an anti-polyethylene glycol recombinant single chain membrane antibody.
"The invention also provides a vector comprising the recombinant nucleotide sequence of the invention.
"The invention also provides a cell comprising the recombinant nucleotide sequence of the invention.
"The invention provides another cell comprising the vector of the invention.
"The invention further provides an anti-polyethylene glycol recombinant single chain membrane antibody, comprising: a first part, comprising a variable light chain-kappa constant (VL-CK) region, and an amino acid sequence thereof comprising the sequence of SEQ ID No. 5 or SEQ ID No. 6; and a second part, comprising a variable heavy chain-heavy chain first constant (VH-CH1) region, and an amino acid sequence thereof comprising the sequence of SEQ ID No. 7 or SEQ ID No. 8, wherein the first part and the second part is connected by a disulfide bond.
"The invention further provides a method for using a cell, comprising: (a) providing a living being having the cell claimed in claim 6, wherein the cell expresses the anti-polyethylene glycol recombinant single chain membrane antibody on a cell membrane thereof; (b) injecting a polyethylene glycol imaging probe into the living being, wherein the polyethylene glycol imaging probe binds to the anti-polyethylene glycol recombinant single chain membrane antibody, and the polyethylene glycol imaging probe is formed by a polyethylene glycol connecting to an imaging agent; and © using an imaging system to observe a region presenting the anti-polyethylene glycol recombinant single chain membrane antibody in the living being.
"A detailed description is given in the following embodiments with reference to the accompanying drawings."
For additional information on this patent, see: Cheng, Tian-Lu; Roffler, Steve R.; Chuang, Kuo-Hsiang. Recombinant Nucleotide Sequence, Cell Or Vector Containing the Same and Method for Using Cell Containing the Same to Encode Anti-Polyethylene Glycol Monoclonal Antibodies. U.S. Patent Number 8507207, filed
Keywords for this news article include: Alkenes, Genetics, Genomics, Polyenes, Immunology, Hydrocarbons, Reporter Gene, Blood Proteins, Immunoglobulins, Serum Globulins, Organic Chemicals, Polyethylene Glycols, Monoclonal Antibodies,
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
Most Popular Stories
- Slow Week Ahead of December FOMC Meeting
- Hispanics Seek to Grow School Board Members
- GM Bailout Saved 1.2 Million U.S. Jobs, Report Says
- 'Knockout Game': Myth or Menace?
- Questions Remain in Jenni Rivera's Death
- Bitcoin Used to Buy Tesla Car
- Banks Fret as Volcker Vote Approaches
- Paul Walker Fans Pay Respects
- 18 L.A. Sheriff's Deputies Face U.S. Charges
- Yellen Set to Become One of World's Most Powerful Women